^
    Back
    Association details:
    Biomarker:NTRK3 fusion
    Cancer:Soft Tissue Sarcoma
    Drug:Rozlytrek (entrectinib) (ALK inhibitor, TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor, ROS1 inhibitor, JAK2 inhibitor, TNK2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Soft Tissue Sarcoma: Useful in certain circumstances…Entrectinib (for NTRK gene-fusion sarcomas).
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Solid Tumor)
    New
    Excerpt:
    ROZLYTREK is a kinase inhibitor indicated for the treatment of...Adult and pediatric patients older than 1 month of age with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation.
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    DGHO 2020
    Title:

    Entrectinib in NTRK fusion-positive sarcoma: integrated analysis of patients enrolled in STATRK-2, STARTRK-1 and ALKA-372-001

    Published date:
    09/03/2020
    Excerpt:
    In 13 pts with NTRK-fusion positive sarcomas, NTRK1 and NTRK3 gene fusions were detected (53.8% and 46.2%). Six subtypes of soft tissue sarcoma and 7 cases of sarcoma 'not otherwise specified' were reported….In this integrated analysis of global multicentre clinical trials, entrectinib was well tolerated and induced clinically meaningful, durable responses in pts with NTRK-fusion positive sarcomas.
    Trial ID:
    STARTRK-1